Signal12 Inc.
Signal12 is a Phase 3-ready ophthalmic drug company. Our proprietary topical drug, Pro-ocular™, has proven safe and effective in Phase 2 clinical studies, demonstrating significant reductions in the signs and symptoms of ocular Graft-versus-Host Disease (oGvHD)—a chronic, debilitating condition following an allogeneic stem cell transplant. Pro-ocular™ is the only effective treatment for oGvHD, employing transappendageal delivery to precisely target the ophthalmic branch of the trigeminal nerve
Signal12 is actively raising capital to complete its Phase 3 clinical trials and bring Pro-ocular™ to market. For information on investment opportunities, please email Neil Edwards at [email protected]. The company has offices in Greenwich, CT and Boston, MA.
© 2025 Signal 12 Inc. | Email: [email protected]
Understanding Ocular Graft-Versus-Host Disease: Pathophysiology and Clinical Implications
At Signal12 Inc., we are committed to advancing knowledge about complex medical conditions that impact quality of life, such as ocular graft-versus-host disease (oGVHD). This condition, a significant complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT), affects approximately 40-60% of transplant recipients, manifesting as a debilitating ocular surface disorder. oGVHD arises when donor immune cells […]
Diagnostic Challenges in Ocular Graft-Versus-Host Disease: Current Tools and Future Directions
Ocular graft-versus-host disease (oGVHD) is a frequent and debilitating complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), affecting up to 60% of recipients. Accurate diagnosis is critical to initiate timely treatment and prevent irreversible ocular damage, yet the condition’s heterogeneity and overlap with other ocular surface diseases pose significant challenges. Current diagnostic tools, rooted in […]
Therapeutic Advances in Managing Ocular GVHD: From Topical Treatments to Surgical Interventions
Ocular graft-versus-host disease (oGVHD) transforms the eyes into battlegrounds of immune dysregulation post-allo-HSCT, necessitating robust therapeutic strategies. From topical agents to surgical interventions, management has evolved significantly, yet no single approach universally halts progression. This post surveys the therapeutic landscape, emphasizing evidence-based options and cutting-edge developments as of 2025. Topical Treatments First-line therapy targets inflammation […]
The Role of Meibomian Gland Dysfunction in Ocular GVHD: A Critical Yet Overlooked Component
Meibomian gland dysfunction (MGD) is a cornerstone of ocular graft-versus-host disease (oGVHD), driving evaporative dry eye and exacerbating symptoms. Despite its prevalence—affecting up to 80% of oGVHD patients per 2023 studies—MGD remains understudied compared to lacrimal gland pathology. This post examines its role, mechanisms, and implications in oGVHD. MGD in oGVHD: Mechanisms Meibomian glands secrete […]
Biomarkers in Ocular GVHD: Unlocking Precision Diagnosis and Monitoring
Ocular graft-versus-host disease (oGVHD) eludes early detection with traditional tools, driving the search for reliable biomarkers. These molecular signatures, detectable in tears or tissue, promise precision in diagnosing and monitoring this post-allo-HSCT complication. Recent advances in proteomics and cytokine profiling have illuminated oGVHD’s inflammatory underpinnings, offering a path to personalized care. This post explores key […]
The Intersection of Systemic and Ocular GVHD: A Multidisciplinary Perspective
Ocular graft-versus-host disease (oGVHD) rarely occurs in isolation—it’s a facet of systemic chronic GVHD (cGVHD), affecting 60-80% of allo-HSCT recipients with multi-organ involvement. This interplay complicates diagnosis and treatment, requiring collaboration across specialties. This post examines how systemic GVHD influences ocular manifestations, emphasizing the need for integrated care. Systemic GVHD as a Driver Systemic cGVHD, […]
Preventing Ocular GVHD: Strategies Before and After Transplantation
Preventing ocular graft-versus-host disease (oGVHD) could spare allo-HSCT patients significant morbidity, yet proactive strategies remain underexplored. Pre- and post-transplant interventions targeting risk factors and early inflammation offer hope. This post evaluates evidence-based prevention approaches, grounded in current science. Pre-Transplant Strategies Conditioning regimens (e.g., cyclophosphamide, irradiation) damage ocular tissues, increasing oGVHD risk. Reduced-intensity conditioning (RIC) lowers […]
Ocular GVHD in Pediatric Patients: Unique Challenges and Considerations
Ocular graft-versus-host disease (oGVHD) in pediatric allo-HSCT recipients presents distinct challenges, driven by developmental factors and diagnostic hurdles. Though less studied than in adults, it affects 20-40% of young survivors. This post delves into its unique features and management in children. Pediatric-Specific Features Children’s immature immune systems may dampen oGVHD severity, yet smaller ocular structures […]
The Future of Ocular GVHD Research: Innovations on the Horizon
Ocular graft-versus-host disease (oGVHD) research is at a cusp, with innovations in genomics, immunotherapy, and modeling poised to reshape understanding and treatment. This post explores these horizons, spotlighting 2025’s most promising advances. Genomic Insights Gene expression profiling (e.g., HLA-G upregulation) could predict oGVHD risk. A 2024 Nature Communications study linked polymorphisms in IL-10 to lower […]
Ocular GVHD and Dry Eye Disease: Differentiating the Overlap
Ocular graft-versus-host disease (oGVHD) mimics dry eye disease (DED) like Sjögren’s syndrome or meibomian gland dysfunction (MGD), complicating diagnosis. This post dissects their overlap and distinctions, leveraging clinical and molecular insights. Shared Features Both oGVHD and DED present with dryness, photophobia, and tear film instability. Schirmer’s scores <5 mm and corneal staining occur across conditions. […]